COMy 2019 | Prevention and management of adverse events in relapsed myeloma
The general approach for treating multiple myeloma (MM) has progressed from patients receiving a single drug for a short period, to a combination of drugs for an extended period. Michel Delforge, MD, PhD, of the University of Leuven, Leuven, Belgium, explains that this is increasing the appearance of adverse events which not only decrease patient’s quality of life but also overall survival rates. Prof. Delforge discusses the adverse effects that may result from various treatments such as proteasome inhibitors including bortezomib, ixazomib and carfilzomib, and monoclonal antibodies including daratumumab, elotuzumab and isatuximab. Finally, Prof. Delforge touches upon the side effects that have been seen so far with CAR-T therapy and cellular immunotherapy. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
